Ulrike Gnad-Vogt

Ulrike Gnad-Vogt

Technik-/Wissenschafts-/F&E-Leiter bei CureVac SE

Health Technology
Consumer Services

Ursprung des Netzwerks ersten Grades von Ulrike Gnad-Vogt

EinheitArt der EinheitIndustrie
19
Subsidiary Biotechnology 19

Unternehmensgrafik - zweiten Grades

Beziehungen zu mehreren Unternehmen

Unternehmensverbindungen über das persönliche Netzwerk von Ulrike Gnad-Vogt

UnternehmenSektorVerknüpfte PersonenHauptposition
CUREVAC N.V. Pharmaceuticals: Major

Friedrich von Bohlen und Halbach

Craig Tooman

Michael Brosnan

Baron Jean Stéphenne

Hans Tanner

Franz-Werner Haas

Pierre Kemula

Florian von der Muelbe

Ingmar Hoerr

Mathias Hothum

Ralf Clemens

Mariola Fotin-Mleczek

Timothy M. Wright

Debra Stephanie Barker

Bernd Winterhalter

Igor Splawski

Director/Board Member

Director/Board Member

Director/Board Member

Chairman

Director/Board Member

Chief Executive Officer

Director of Finance/CFO

Founder

Founder

Director/Board Member

Director/Board Member

Chief Tech/Sci/R&D Officer

Director/Board Member

Director/Board Member

Corporate Officer/Principal

Chief Tech/Sci/R&D Officer

Miscellaneous Commercial Services

Baron Jean Stéphenne

Ralf Clemens

Jean Stephenne

Chief Executive Officer

Corporate Officer/Principal

Chief Executive Officer

Medical Specialties

Friedrich von Bohlen und Halbach

Mathias Hothum

Chairman

Director/Board Member

Pharmaceuticals: Major

Baron Jean Stéphenne

Jean Stephenne

Chairman

Chief Executive Officer

Engineering & Construction

Baron Jean Stéphenne

Jean Stephenne

Chairman

Director/Board Member

IMMATICS N.V. Biotechnology

Friedrich von Bohlen und Halbach

Mathias Hothum

Director/Board Member

Director/Board Member

MORPHOSYS AG Biotechnology

Michael Brosnan

Daniel L. Menichella

Director/Board Member

Corporate Officer/Principal

Biotechnology

Baron Jean Stéphenne

Jean Stephenne

Director/Board Member

Director/Board Member

TIGENIX NV Medical Specialties

Baron Jean Stéphenne

Jean Stephenne

Chairman

Chairman

Investment Managers

Friedrich von Bohlen und Halbach

Mathias Hothum

Private Equity Investor

Chief Executive Officer

Miscellaneous Commercial Services

Friedrich von Bohlen und Halbach

Mathias Hothum

Chief Executive Officer

Director/Board Member

AC IMMUNE SA Pharmaceuticals: Major

Friedrich von Bohlen und Halbach

Mathias Hothum

Director/Board Member

Director/Board Member

COSMO PHARMACEUTICALS N.V. Pharmaceuticals: Major

Friedrich von Bohlen und Halbach

Hans Tanner

Director/Board Member

Director of Finance/CFO

Eberhard Karls Universität Tübingen College/University

Florian von der Muelbe

Ingmar Hoerr

Doctorate Degree

Doctorate Degree

Packaged Software

Friedrich von Bohlen und Halbach

Mathias Hothum

Chairman

Director/Board Member

Medical/Nursing Services

Baron Jean Stéphenne

Jean Stephenne

Chairman

Director/Board Member

Biotechnology

Friedrich von Bohlen und Halbach

Mathias Hothum

Chairman

Director/Board Member

dievini Verwaltungs GmbH

Friedrich von Bohlen und Halbach

Mathias Hothum

Chief Executive Officer

Chief Executive Officer

Pharmaceuticals: Major

Friedrich von Bohlen und Halbach

Hans Tanner

Director/Board Member

Director/Board Member

GROUPE BRUXELLES LAMBERT SA Financial Conglomerates

Baron Jean Stéphenne

Jean Stephenne

Director/Board Member

Director/Board Member

2INVEST AG Financial Conglomerates

Friedrich von Bohlen und Halbach

Franz-Werner Haas

Director/Board Member

Compliance Officer

BNP PARIBAS FORTIS SA Major Banks

Baron Jean Stéphenne

Jean Stephenne

Director/Board Member

Director/Board Member

HEIDELBERG PHARMA AG Pharmaceuticals: Major

Friedrich von Bohlen und Halbach

Mathias Hothum

Director/Board Member

Director/Board Member

Medical Specialties

Hans Tanner

Mathias Hothum

Director/Board Member

Director/Board Member

Biotechnology

Baron Jean Stéphenne

Jean Stephenne

Chairman

Corporate Officer/Principal

Real Estate Development

Florian von der Muelbe

Chief Executive Officer

Miscellaneous Commercial Services

Franz-Werner Haas

Chief Executive Officer

IPSEN Pharmaceuticals: Major

Pierre Kemula

Public Communications Contact

PIXIUM VISION Medical Specialties

Pierre Kemula

Director of Finance/CFO

London School of Economics & Political Science College/University

Pierre Kemula

Undergraduate Degree

Financial Conglomerates

Mathias Hothum

Chief Executive Officer

Real Estate Development

Mathias Hothum

Chief Executive Officer

University of Mannheim College/University

Mathias Hothum

Undergraduate Degree

ESB Business School College/University

Florian von der Muelbe

Masters Business Admin

BIOTEST AG Pharmaceuticals: Other

Florian von der Muelbe

Corporate Officer/Principal

Otto-von-Guericke-Universität Magdeburg College/University

Mathias Hothum

Doctorate Degree

Donau-Universität Krems College/University

Ingmar Hoerr

Masters Business Admin

Containers/Packaging

Franz-Werner Haas

Chief Executive Officer

Universität Saarbrücken College/University

Franz-Werner Haas

Graduate Degree

The University of North Carolina at Charlotte College/University

Daniel L. Menichella

Masters Business Admin

Investment Banks/Brokers

Hans Tanner

Corporate Officer/Principal

Investment Managers

Hans Tanner

Director/Board Member

Investment Managers

Hans Tanner

Corporate Officer/Principal

Investment Banks/Brokers

Hans Tanner

Corporate Officer/Principal

Miscellaneous Commercial Services

Hans Tanner

Director/Board Member

CASSIOPEA S.P.A. Pharmaceuticals: Major

Hans Tanner

Director of Finance/CFO

Biotechnology

Daniel L. Menichella

Corporate Officer/Principal

Statistik

International

Deutschland 23
Belgien 9
Schweiz 7
Vereinigte Staaten 4
Italien 4

Sektoral

Health Technology 22
Finance 13
Consumer Services 9
Commercial Services 5
Industrial Services 2

Operativ

Director/Board Member 117
Corporate Officer/Principal 44
Chairman 41
Chief Executive Officer 28
Independent Dir/Board Member 18
  1. Börse
  2. Insiders
  3. Ulrike Gnad-Vogt
  4. Unternehmensverbindungen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT